MSFT 425.025 -0.9035% AAPL 220.43 0.8648% NVDA 115.85 1.4004% GOOGL 172.44 -0.1101% GOOG 174.27 -0.0573% AMZN 182.99 1.1945% META 460.09 -0.2558% AVGO 152.64 0.859% TSLA 224.8499 4.102% TSM 161.61 1.1327% LLY 823.56 -4.2238% V 257.56 1.3338% JPM 209.535 0.453% UNH 562.83 0.5502% NVO 129.31 -1.7401% WMT 70.206 -0.5581% LVMUY 143.15 0.9022% XOM 116.85 1.5999% LVMHF 714.04 0.4982% MA 436.96 1.0429%
Last update at 2024-07-25T16:47:00Z
Omnicell to Release Second Quarter 2024 Financial Results on August 1, 2024
Mon 15 Jul 24, 08:01 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -2.45300M | 66.01M | 29.35M | 73.93M | 35.62M |
| Minority interest | - | - | - | - | - |
| Net income | 5.65M | 77.85M | 32.19M | 61.34M | 37.73M |
| Selling general administrative | 486.34M | 389.43M | 307.61M | 289.92M | 263.10M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 588.99M | 554.65M | 413.29M | 436.91M | 372.33M |
| Reconciled depreciation | 99.17M | 84.93M | 71.59M | 64.12M | 51.35M |
| Ebit | -2.32300M | 89.51M | 35.53M | 78.35M | 44.39M |
| Ebitda | 96.85M | 174.44M | 107.12M | 142.47M | 95.74M |
| Depreciation and amortization | 99.17M | 84.93M | 71.59M | 64.12M | 51.35M |
| Non operating income net other | -0.13000M | -23.50000M | -6.17700M | -4.41900M | -8.77600M |
| Operating income | -2.32300M | 89.51M | 35.53M | 78.35M | 44.39M |
| Other operating expenses | 1298.27M | 1042.51M | 856.68M | 818.67M | 742.92M |
| Interest expense | 0.13M | -23.50000M | -6.17700M | -4.41900M | 8.78M |
| Tax provision | -8.10100M | -11.84200M | -2.84500M | 12.60M | -2.11300M |
| Interest income | - | - | - | 4.42M | 8.78M |
| Net interest income | -0.13000M | -23.50000M | -6.17700M | -4.41900M | -8.77600M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -8.10100M | -11.84200M | -2.84500M | 12.60M | -2.11300M |
| Total revenue | 1295.95M | 1132.02M | 892.21M | 897.03M | 787.31M |
| Total operating expenses | 591.31M | 465.15M | 377.77M | 358.56M | 327.94M |
| Cost of revenue | 706.96M | 577.37M | 478.92M | 460.12M | 414.98M |
| Total other income expense net | -0.13000M | -23.50000M | -6.17700M | -4.41900M | -8.77600M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 5.65M | 77.85M | 32.19M | 61.34M | 37.73M |
| Net income applicable to common shares | 5.65M | 77.85M | 32.19M | 61.34M | 37.73M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 2226.88M | 2210.76M | 2142.50M | 1824.50M | 1240.81M |
| Intangible assets | 277.83M | 242.91M | 277.62M | 168.21M | 124.87M |
| Earning assets | - | - | - | - | - |
| Other current assets | 52.60M | 77.36M | 48.33M | 41.04M | 15.18M |
| Total liab | 1037.92M | 1080.62M | 995.81M | 857.00M | 395.56M |
| Total stockholder equity | 1188.95M | 1130.14M | 1146.69M | 967.50M | 845.25M |
| Deferred long term liab | - | 2.10M | 51.70M | 4.25M | 39.09M |
| Other current liab | 179.96M | 235.35M | 204.30M | 123.86M | 89.66M |
| Common stock | 0.06M | 0.06M | 0.05M | 0.05M | 0.05M |
| Capital stock | 0.06M | 0.06M | 0.05M | 0.05M | 0.05M |
| Retained earnings | 370.36M | 390.73M | 368.57M | 290.72M | 258.79M |
| Other liab | - | 46.20M | 79.74M | 64.48M | 57.89M |
| Good will | 735.81M | 734.27M | 738.90M | 499.31M | 336.54M |
| Other assets | - | 138.99M | 225.59M | 268.50M | 100.72M |
| Cash | 500.98M | 330.36M | 349.05M | 485.93M | 127.21M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 367.79M | 428.45M | 876.16M | 276.42M | 237.00M |
| Current deferred revenue | 132.28M | 118.95M | 112.20M | 100.05M | 90.89M |
| Net debt | 113.11M | 286.38M | 179.01M | 30.17M | -26.54100M |
| Short term debt | 10.52M | 10.76M | 488.15M | 12.20M | 10.06M |
| Short long term debt | - | - | 488.15M | - | - |
| Short long term debt total | 614.09M | 616.74M | 528.06M | 516.10M | 100.67M |
| Other stockholder equity | 831.97M | 756.44M | 786.47M | 682.25M | 595.86M |
| Property plant equipment | - | 93.96M | 119.69M | 59.07M | 54.25M |
| Total current assets | 927.57M | 881.81M | 780.70M | 829.41M | 483.24M |
| Long term investments | 42.95M | 32.92M | 18.39M | 22.16M | 19.75M |
| Net tangible assets | - | 152.96M | 130.17M | 967.50M | 845.25M |
| Short term investments | 11.87M | 11.49M | 10.66M | 10.25M | - |
| Net receivables | 263.89M | 299.47M | 240.89M | 190.12M | 218.36M |
| Long term debt | 569.66M | 566.57M | - | 467.20M | 50.00M |
| Inventory | 110.10M | 147.55M | 119.92M | 96.30M | 108.01M |
| Accounts payable | 45.03M | 63.39M | 71.51M | 40.31M | 46.38M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -13.43200M | -17.08700M | -8.40700M | -5.52200M | -9.44600M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 0.06M | 0.05M | 0.05M | 0.05M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | 390.73M | 368.57M | 290.72M | 258.79M |
| Treasury stock | - | -290.31900M | -238.10900M | -238.10900M | -185.07400M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 64.37M | 164.50M | 191.31M | 176.21M | 151.90M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 1299.31M | 1328.95M | 1361.79M | 995.09M | 757.57M |
| Capital lease obligations | 44.43M | 50.17M | 39.91M | 48.90M | 60.73M |
| Long term debt total | - | 566.57M | - | 467.20M | 50.00M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -58.66900M | -412.49800M | -279.86600M | -61.66400M | -54.37400M |
| Change to liabilities | 10.64M | 53.26M | 17.12M | 19.44M | 11.82M |
| Total cashflows from investing activities | -58.66900M | -412.49800M | -279.86600M | -61.66400M | -54.37400M |
| Net borrowings | - | - | 408.49M | -92.32100M | -77.00000M |
| Total cash from financing activities | -20.95300M | 47.36M | 456.27M | -23.47900M | -13.59700M |
| Change to operating activities | 0.29M | 10.06M | -13.22100M | 0.52M | 8.37M |
| Net income | 5.65M | 77.85M | 32.19M | 61.34M | 37.73M |
| Change in cash | -2.78500M | -134.30000M | 362.71M | 60.02M | 34.77M |
| Begin period cash flow | 355.62M | 489.92M | 127.21M | 67.19M | 32.42M |
| End period cash flow | 352.83M | 355.62M | 489.92M | 127.21M | 67.19M |
| Total cash from operating activities | 77.78M | 231.81M | 185.87M | 145.01M | 103.97M |
| Issuance of capital stock | - | 0.00000M | 0.00000M | 37.81M | 39.57M |
| Depreciation | 99.17M | 84.93M | 71.59M | 64.12M | 51.35M |
| Other cashflows from investing activities | -11.13300M | -383.53100M | -257.02400M | -45.77000M | -30.67700M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -30.11500M | -25.69500M | 12.36M | -8.12300M | -6.76300M |
| Change to account receivables | -60.35700M | -43.22000M | 12.03M | -23.52000M | -6.19200M |
| Sale purchase of stock | -52.21000M | 67.35M | -53.03500M | 78.51M | 70.18M |
| Other cashflows from financing activities | 31.26M | 47.36M | 709.30M | 28.71M | 23.84M |
| Change to netincome | 31.61M | 50.32M | 38.42M | 33.16M | 23.31M |
| Capital expenditures | 60.74M | 58.34M | 54.87M | 61.66M | 54.37M |
| Change receivables | -75.71100M | -37.62700M | 33.96M | -25.23900M | -7.87200M |
| Cash flows other operating | 44.61M | 10.61M | -15.61600M | 8.68M | -7.90600M |
| Exchange rate changes | - | -0.97400M | 0.44M | 0.15M | -1.22700M |
| Cash and cash equivalents changes | -1.84100M | -134.30000M | 362.71M | 60.02M | 34.77M |
| Change in working capital | -73.46600M | -3.34000M | 37.30M | -15.81000M | -10.71800M |
| Stock based compensation | 68.25M | 53.16M | 44.70M | 34.05M | 28.89M |
| Other non cash items | 15.50M | 22.48M | 6.63M | 2.65M | 2.42M |
| Free cash flow | 17.04M | 173.47M | 131.00M | 83.34M | 49.59M |
Sector: Healthcare Industry: Health Information Services
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| OMCL Omnicell Inc |
-0.07 0.24% | 29.55 | - | 29.50 | 1.09 | 1.05 | 1.21 | 22.79 |
| GEHC GE HealthCare Technologies Inc. |
1.08 1.36% | 80.77 | 22.91 | 20.12 | 2.01 | 5.52 | 2.39 | 13.30 |
| VEEV Veeva Systems Inc Class A |
5.39 2.93% | 189.64 | 54.61 | 33.22 | 12.83 | 6.73 | 11.14 | 58.84 |
| MTHRF M3 Inc |
- -% | 9.07 | 29.72 | 25.00 | 0.05 | 4.38 | 0.04 | 0.12 |
| MTHRY M3 Inc |
0.10 2.10% | 4.86 | 31.84 | 26.25 | 0.05 | 4.60 | 0.04 | 0.12 |
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
4220 North Freeway, Fort Worth, TX, United States, 76137
| Name | Title | Year Born |
|---|---|---|
| Mr. Randall A. Lipps | Founder, Exec. Chairman, Pres & CEO | 1957 |
| Mr. Peter J. Kuipers | Exec. VP & CFO | 1972 |
| Ms. Christine Mellon | Exec. VP, Chief Admin. & People Officer | 1963 |
| Mr. Scott Peter Seidelmann | Exec. VP & Chief Commercial Officer | 1976 |
| Mr. Joseph Brian Spears | Sr. VP, Chief Accounting Officer & Corp. Controller | 1960 |
| Mr. Giri Chodavarapu | Sr. VP & Chief Information Officer | NA |
| Ms. Kathleen Nemeth | Sr. VP of Investor Relations | NA |
| Mr. Corey J. Manley | Sr. VP & Chief Legal Officer | NA |
| Ms. Roxanne Turner | Sr. VP of Corp. Responsibility and Chief Compliance & Privacy Officer | NA |
| Mr. Jorge R. Taborga | Exec. VP of Engineering & Integration Management Officer | 1959 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...